| Brian Center Health & Retirement/cabarrus | |
| 250 Bishop Lane, Concord, North Carolina 28025 | |
| (704) 788-6400 | |
| Name | Brian Center Health & Retirement/cabarrus |
|---|---|
| Location | 250 Bishop Lane, Concord, North Carolina |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 90 |
| Occupancy Rate | 86% |
| Medicare ID (CCN) | 345362 |
| Legal Business Name | Ssc Concord Operating Company Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1538808340 |
| Organization Name | GREENS AT CABARRUS LLC |
| Address | 250 Bishop Ln, Concord, NC 28025 |
| Phone Number | 704-788-6400 |
News Archive
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today it has initiated its ATHENA natural history of disease study in patients with Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.
The future is bleak for children whose behavior seriously goes against the norm at a tender age. Early and long-term interventions make all the difference.
An approach to treatment that focuses on recovery from mental illness, not the treatment of it, is gaining national acclaim for the Medical College of Georgia Department of Psychiatry and Health Behavior at Georgia Health Sciences University.
Stem cell genes seek each other in the cell nucleus. So a study by the Hubrecht Institute in Utrecht, the Netherlands, has found, published this week in Nature. "It's a new way of looking at DNA."
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today it has initiated its ATHENA natural history of disease study in patients with Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.
The future is bleak for children whose behavior seriously goes against the norm at a tender age. Early and long-term interventions make all the difference.
An approach to treatment that focuses on recovery from mental illness, not the treatment of it, is gaining national acclaim for the Medical College of Georgia Department of Psychiatry and Health Behavior at Georgia Health Sciences University.
Stem cell genes seek each other in the cell nucleus. So a study by the Hubrecht Institute in Utrecht, the Netherlands, has found, published this week in Nature. "It's a new way of looking at DNA."
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $57389 |
| Number of Payment Denials | 1 |
| Total Number of Penalties | 2 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 14.22 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 11.7 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 68.67 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.04 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 2.76 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4.68 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 6.82 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 94.61 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.17 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 27.61 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.45 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.6 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 63.48 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 78.58 | 82.93 |
News Archive
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today it has initiated its ATHENA natural history of disease study in patients with Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.
The future is bleak for children whose behavior seriously goes against the norm at a tender age. Early and long-term interventions make all the difference.
An approach to treatment that focuses on recovery from mental illness, not the treatment of it, is gaining national acclaim for the Medical College of Georgia Department of Psychiatry and Health Behavior at Georgia Health Sciences University.
Stem cell genes seek each other in the cell nucleus. So a study by the Hubrecht Institute in Utrecht, the Netherlands, has found, published this week in Nature. "It's a new way of looking at DNA."
› Verified 5 days ago
Accordius Health At Concord Location: 515 Lake Concord Road Ne, Concord, North Carolina 28025 Phone: (704) 784-4494 | |
Universal Health Care & Rehab Location: 430 Brookwood Avenue Ne, Concord, North Carolina 28025 Phone: (704) 788-4115 | |
Five Oaks Manor Location: 413 Winecoff School Road, Concord, North Carolina 28027 Phone: (704) 788-2131 | |
Brian Center Health & Retirement/cabarrus Location: 250 Bishop Lane, Concord, North Carolina 28025 Phone: (704) 788-6400 | |
The Gardens Of Taylor Glen Ret Com Location: 3700 Taylor Glen Lane, Concord, North Carolina 28027 Phone: (704) 788-6510 |